FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia

Hayley S. Ma,1 Bao Nguyen,1 Amy S. Duffield,2 Li Li,1 Allison Galanis,1 Allen B. Williams,1 Patrick A. Brown,1,3 Mark J. Levis,1 Daniel J. Leahy,4 and Donald Small1,3

1Department of Oncology, 2Pathology, 3Pediatrics, and 4Biophysics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Running title: TTT-3002 overcomes FLT3 TKI limitations

Keywords: FLT3 inhibitor, drug resistance, acute myeloid leukemia

Financial support: The project described was supported by grants from the Alex's Lemonade Stand Foundation for Childhood Cancer and NIH NCI (CA90668 and CA70970) as well as funds from the Giant Food Pediatric Cancer Research Program. D.S. is also supported by the Kyle Haydock Professorship.

Corresponding author:
Donal Small, M.D., Ph.D., Address: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CRBI Room 251, 1650 Orleans Street, Baltimore, MD 21231; Phone: 410-614-0994; Fax: 410-955-8897; E-mail: donsmall@jhmi.edu
Conflict-of-interest disclosure: The authors disclose no potential conflicts of interest.

Word count for abstract: 216
Word count for text (excluding references): 4997
Number of Figures: 6
Number of Tables: 1

Precis

A novel small molecule inhibitor of FLT3 can overcome all mutations documented to date in this driver tyrosine kinase in AML patients, also exhibiting superior pharmacological properties that lend appeal as an effective next-gen therapeutic in this setting.

Abstract

There have been a number of clinical trials testing the efficacy of FLT3 tyrosine kinase inhibitors (TKIs) in acute myeloid leukemia (AML) patients harboring a constitutively activating mutation in FLT3. However, there has been limited efficacy, most often due to inadequate achievement of FLT3 inhibition through a variety of mechanisms. In a previous study, TTT-3002 was identified as a novel FLT3 inhibitor with the most potent activity to date against FLT3 internal tandem duplication (FLT3/ITD) mutations. Here the activity of TTT-3002 is demonstrated against a broad spectrum of FLT3 activating point mutations (FLT3/PMs), including the most frequently occurring D835 mutations. The compound is also active against a number of point mutations selected for in FLT3/ITD alleles that confer resistance to other TKIs, including...
the F691L gatekeeper mutation. TTT-3002 maintains activity against relapsed AML patient samples that are resistant to sorafenib and AC220. Studies utilizing human plasma samples from healthy donors and AML patients indicate that TTT-3002 is only moderately protein bound compared to several other TKIs currently in clinical trials. Tumor burden of mice in a FLT3 TKI-resistant transplant model is significantly improved by oral dosing of TTT-3002. Therefore, TTT-3002 has demonstrated preclinical potential as a promising new FLT3 TKI that may overcome some of the limitations of other TKIs in the treatment of FLT3-mutant AML.

Introduction

FMS-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that is commonly mutated in acute myeloid leukemia (AML). Approximately 23% of patients are found to harbor a constitutively activating FLT3/ITD mutation that confers poor prognosis (1). Kinase activating FLT3/PMs such as those reported in the tyrosine kinase domain are also frequently observed (7-10% of patients) (2). Thus, mutant FLT3 is an attractive therapeutic target in the treatment of this disease.

A number of clinical trials for AML patients with FLT3 mutations have been performed using novel tyrosine kinase inhibitors (TKIs) that target FLT3 (3). However, there have been limitations in the responses observed in patients on these trials, often related to insufficient achievement of thorough FLT3 inhibition. An illustrative example is lestaurtinib (CEP-701), an indolocarbazole that showed activity in Phase 1 and 2 trials, though only in those patients in which a high level of inhibition of FLT3 signaling was
achieved. It failed in a randomized Phase 3 trial to improve remission and survival rates for relapsed FLT3 mutant patients for those randomized to chemotherapy plus CEP-701 vs. those receiving chemotherapy alone in part due to failure to achieve inhibition in a large enough fraction of patients (4, 5). A potential reason for the failure of CEP-701 to effectively inhibit FLT3 signaling *in vivo* was a high level of human plasma protein binding (6). This shifts the IC$_{50}$ against FLT3 from 2-3nM in assays conducted in media with 10% fetal bovine serum (FBS, typical for most *in vitro* culture conditions) to 700nM in 100% human plasma (reflective of *in vivo* binding in patients) (7).

A number of FLT3 TKI active against FLT3/ITD have little activity against FLT3/PMs, such as the most frequently occurring D835Y mutation. Sorafenib is a biaryl urea compound that targets multiple tyrosine kinases including FLT3/ITD (8). The results of clinical studies using sorafenib in combination with chemotherapy are promising, demonstrating reduction in bone marrow (BM) and/or peripheral blood (PB) blasts as well as increased CR rates in FLT3/ITD$^+$ AML patients (9-11). Quizartinib (AC220) is another biaryl urea FLT3 inhibitor that has demonstrated significant responses in FLT3/ITD$^+$ AML patients in recent trials (12, 13). However, both sorafenib and AC220 are inactive against many FLT3/PMs, including the D835Y mutation, and thus do not benefit patients harboring this mutation (14-16).

Finally treatment failure has also been observed due to the selection for resistance-conferring point mutations that have appeared in FLT3/ITD-expressing AML patients following TKI treatment. These mutations either occur in residues within the ATP
binding pocket or to residues thought to affect protein structure in ways that also affect the binding of the drug allosterically (3). Midostaurin (PKC412) is a FLT3 TKI that demonstrated reduction of blasts in a Phase 2 trial of relapsed or refractory AML patients (17) and is moderately active against a number of known FLT3/PMs (14). However, in a trial of relapsed/refractory AML patients, PKC412 selected for a mutation at residue N676K in a FLT3/ITD patient that conferred drug resistance (18). A number of initially responsive patients on AC220 and sorafenib trials were also found to have selected for additional resistance-conferring point mutations in the FLT3/ITD allele. These frequently include a F691L mutation (analogous to the T315I mutation in BCR/ABL that confers resistance to Gleevec) or D835 mutations (Y/F/V/H) in the kinase domain (19, 20). Crenolanib is a next generation FLT3 inhibitor that is currently in Phase II trials of relapsed AML with FLT3/D835 activating mutations. This compound has demonstrated in vitro and in vivo activity against FLT3/D835 mutations (Y/F/V/H) and the dual FLT3-D835(Y/H)/ITD mutant receptors (21, 22). However, it is unable to target the F691L mutation, and therefore has the potential to select for this resistance mutation in trials. Currently, the most potent activity against the F691L mutation in vitro has been observed for the BCR-ABL inhibitor ponatinib. However, ponatinib still shows a nearly 20-fold shift in IC₅₀ for the F691L mutation compared to FLT3/ITD alone, and plasma samples from patients show marginal levels of inhibition in the plasma inhibitory activity (PIA) assay against the F691L mutation and no activity against D835 mutations (23). Therefore, the search for novel FLT3 TKIs that overcome some of the mechanisms that result in persistent FLT3 activation is necessary to improve the cure rate for this disease.
We sought to explore the ability of a novel FLT3 inhibitor, TTT-3002, to overcome several mechanisms of drug resistance associated with current FLT3 TKIs. We have previously reported that TTT-3002 is the most potent FLT3 inhibitor discovered to date, with picomolar IC₅₀ values against FLT3/ITD phosphorylation (24). Here we assess the activity of TTT-3002 against a broad spectrum of known FLT3/PMs, as well as a number of TKI resistance mutations within the \textit{FLT3/ITD} allele. Finally, the protein binding characteristics of TTT-3002 in human plasma are explored to predict whether it is likely to maintain activity against FLT3/ITD and FLT3/PM in patients.

**Materials and Methods**

**Compounds**

TTT-3002 was a generous gift of Hanno Roder from TauTaTis, Inc. (San Diego, CA). CEP-701, AC220, sorafenib and PKC412 were purchased from LC Laboratories. Compounds were dissolved in 100% DMSO and prepared as 10µM stock solutions in RPMI with 0.1% DMSO and stored at -80°C.

**Immunoprecipitation and Western Blotting**

Cells were cultured in the presence of inhibitor for 1 hour at 37°C, and FLT3 and phospho-FLT3 expression was analyzed by performing immunoprecipitation of whole cell extracts for FLT3 (S-18), followed by SDS-PAGE and Western blotting as described previously (24). Other proteins were detected from whole cell lysates using the indicated
antibodies and a horseradish peroxidase conjugated goat anti-rabbit secondary antibody followed by ECL.

**Flow cytometry analysis**

Flow cytometry analysis was performed using a BD FACSCalibur machine (BD Biosciences). The following anti-mouse monoclonal antibodies and dyes were used for the staining of cellular markers: CD135-PE, Annexin V-APC, 7-amino-actinomycin (7-AAD, BD Biosciences). For hematopoietic stem/progenitor staining, femur, tibia, hips, and spine were isolated from Ba/F3-F691L/ITD Luc+ transplant recipient mice. BM cells were isolated by crushing and stained with anti-mouse CD135-PE (5 µL) for 40 minutes. Apoptosis was measured by incubating treated cells with Annexin V-APC antibody and 7-AAD for 10 minutes according to the manufacturer’s instructions (BD Biosciences). All data were analyzed by FlowJo analysis software (Tree Star).

**Macromolecular Modeling**

To position TTT-3002, CEP-701, PKC412, AC220 and sorafenib on the FLT3 kinase structure (1RJB) (25), the kinase domains of the VEGFR2 kinase complexed with sorafenib (4ASD) (26) and the C-terminal Src kinase complexed with staurosporine (1BYG) (27) were superimposed on the FLT3 kinase structure. The program COOT (28) was used to generate the N676K, F691L, and G697R substitutions by replacing the native side chain with the most common rotamer of the resistance variant.

**Transplantation experiments**
Transplantation of Ba/F3-F691L/ITD luciferase expressing cells was performed as described previously (24, 29). For engraftment, $2 \times 10^6$ cells were injected by tail vein into female BALB/C mice (Day 0). Starting seven days later, engraftment was confirmed by bioluminescence imaging of luciferase-expressing cells and mice were then treated with 6 mg/kg of TTT-3002 hydrochloride suspended by brief sonication 1 h prior to dosing in 1mM HCl twice daily or 10 mg/kg of sorafenib suspended in 30% (w/v) Cremophor EL, 30% w/v PEG 400, 10% ethanol, and 10% glucose (all Sigma-Aldrich), as described previously, once daily by oral gavage for 2 weeks (30). Mice were imaged by injecting D-luciferin (3 mg intraperitoneally) and visualized on an IVIS Spectrum imager (Caliper LifeSciences) using Living Image software for analysis on day 7 post-inoculation in order to monitor engraftment. BM cells were harvested from the femur, tibia and hips by crushing, and spleens were harvested by mechanically filtering through a 40µm nylon cell strainer (BD).

**Patient Samples**

Human AML BM samples were collected under an institutionally-approved protocol with informed patient consent in accordance with the Declaration of Helsinki. Mononuclear cells were isolated by Ficoll centrifugation and cryopreserved until use in liquid nitrogen. All studies used freshly thawed cells. Plasma was purified by centrifugation ($450 \times g$) and stored at -20°C.

**Statistical Analysis**
Statistical analysis was performed with Student's t test by use of the GraphPad software analysis program (Prism). P values of less than .05 were considered to be statistically significant. All data are presented as the mean ± standard deviation (SD).

Additional information on Materials and Methods can be found online in Supplemental Information.

Results

**TTT-3002 activity against FLT3 activating point mutations**

Many FLT3 activating point mutations have been observed in AML patients and the response of each FLT3/PM to each FLT3 TKI varies widely (2, 3, 31-34). Notably, AC220 has reduced potency against many FLT3/PMs, and is thus ineffective in treating patients with these mutations. To predict the ability of TTT-3002 to inhibit FLT3/PM autophosphorylation, we generated a panel of twelve stably transfected Ba/F3 cell lines in which FLT3/PMs known to transform the cells to IL-3 independence were introduced, and its activity was compared directly to the cytotoxic activity of AC220 (supplemental Table 1). This panel included the most frequently occurring D835 mutations (Y/F/V/H) and other D835 variants, as well as I836 mutations and mutations in the juxtamembrane domain (V579A and D593Δ). TTT-3002 is a potent inhibitor of all twelve mutants screened, with proliferation IC₅₀ values in the low nanomolar range, and is thus active against many FLT3/PMs for which AC220 is completely ineffective (Fig. 1A and supplemental Table 1). Treatment with TTT-3002, but not AC220, results in a marked
induction of apoptosis of FLT3/PM-expressing cells as determined by Annexin V binding, reaching the half maximal effective concentration (EC₅₀) by 10-50nM for all mutants. In contrast, activity against FLT3/ITD-expressing cells is similar for the two compounds (Fig. 1B). TTT-3002 inhibits FLT3/PM phosphorylation in a dose-dependent manner, achieving greater than 50% inhibition of FLT3 signaling at a concentration of 0.5nM (Fig. 1C, D). In contrast, AC220 failed to achieve thorough FLT3/PM inhibition even at 10nM concentrations (Fig. 1C). Therefore, TTT-3002’s broad spectrum of activity against FLT3/PMs increases its therapeutic potential in patients with this class of non-ITD activating FLT3 mutations.

**TTT-3002 activity against FLT3 TKI resistance mutations**

The phenomenon of drug resistance caused by selection for FLT3 point mutations is occurring at increasing frequency as higher levels of inhibition by FLT3 TKIs are achieved in clinical trials of FLT3/ITD AML patients (19, 20, 35-37). To test the ability of TTT-3002 to successfully treat some of these resistance mutations, site-directed mutagenesis was used to generate a series of FLT3/ITD TKI resistant cell lines (29, 38). The activity of TTT-3002 was then compared to that of a number of other FLT3 TKIs currently in clinical trials. TTT-3002 is the most potent inhibitor against the six FLT3/ITD TKI resistance mutants screened, with proliferation IC₅₀ values of approximately 1nM (with the single exception of Ba/F3-G697R/ITD, IC₅₀=11nM) (Fig. 2A and Table 1). It effectively inhibits resistance mutations against which other TKIs are ineffective. The activities of CEP-701, sorafenib, AC220 and PKC412 against these resistance mutants is similar to what has been reported previously (21, 29). TTT-3002 inhibits FLT3
phosphorylation in a dose-dependent manner in FLT3/ITD TKI resistant cells, often with an IC₅₀ of less than 250-500pM (Figure 2B). The extent of inhibition is also significantly greater than the other TKIs at a fixed concentration of 20nM, achieving 75-99% inhibition of FLT3 signaling (Fig. 2C, D). TTT-3002 also inhibits phosphorylation of downstream targets of FLT3 signaling, such as STAT5, AKT and MAPK (Fig. 2E, supplemental Fig. 1). Therefore, this compound’s broad spectrum of activity against FLT3/ITD TKI resistance mutations may enable it to successfully treat FLT3/ITD AML patients who have become resistant to other FLT3 TKIs.

Molecular modeling of the TKI-FLT3 binding interaction

To understand the patterns of drug resistance displayed by different FLT3 TKIs in this study, the positions of staurosporine-like (TTT-3002, CEP-701 and PKC412) and sorafenib-like inhibitors (sorafenib and AC220) bound to FLT3 were modeled (Fig. 3). Although crystal structures of the FLT3 kinase bound to these inhibitors have not been determined, crystal structures of the related VEGFR2 and C-terminal Src kinases bound to sorafenib (PDB code 4ASD) and staurosporine (PDB code 1BYG), respectively, have been determined (25, 26). Assuming that these drugs bind similarly to FLT3 kinase, we superimposed the kinase domains of the VEGFR2:sorafenib and C-terminal Src kinase:staurosporine complexes on the FLT3 kinase structure to generate a model for how sorafenib and staurosporine are likely to bind to FLT3. Inspecting these models to investigate the likely effects of amino-acid substitutions in FLT3 known to confer resistance to TKIs in clinical trials shows that substituting arginine for glycine at position 697 places side-chain atoms within 2.8 Å and 3.5 Å of atoms of staurosporine-like and...
sorafenib-like inhibitors, respectively, likely leading to steric clashes. Glycine 697 adopts main-chain dihedral angles (phi of 60°, psi of -170°) that are unfavorable for non-glycine amino-acids, and an arginine substitution at this site would also lead to at least local changes in main-chain conformation. It has been proposed that the F691 residue forms a stabilizing π-π stacking interaction with AC220, and thus a mutation to a Leu would result in reduced TKI binding affinity (20). TTT-3002 is predicted to bind FLT3 without making direct contact with the F691 residue, and thus is unaffected by mutations at this site. Likewise, the closer proximity of F691 and N676 to sorafenib compared to staurosporine atoms likely underlies the trend for substitutions at these sites to confer resistance to sorafenib-like but not staurosporine-like inhibitors.

**TTT-3002 overcomes drug resistance in vivo**

To assess the ability of TTT-3002 to overcome TKI resistance in vivo, a bioluminescent mouse model of leukemia was utilized in which luciferase expressing Ba/F3-F691L/ITD cells (Ba/F3-F691L/ITD Luc+) were transplanted into syngeneic BALB/c recipients. The Ba/F3-F691L/ITD Luc+ cell line is sensitive to TTT-3002 treatment in vitro with a proliferation IC$_{50}$ of <250pM for TTT-3002 vs. >50nM for sorafenib (Fig. 4A). Engraftment was confirmed on Day 7 by bioluminescence imaging of luciferase-expressing cells following tail vein injection of $2 \times 10^6$ cells in recipient mice, which were then administered TTT-3002 and sorafenib at the maximum tolerated dose of 6 mg/kg b.i.d. and 10 mg/kg q.d., respectively, or vehicle control (1mM HCl b.i.d.) for 14 days (n=4 per group, Fig. 4B) (30). There was no significant effect on hemoglobin or platelet count with this drug administration schedule, with counts in the normal range at the end
of the treatment period (11.0-15.1 g/dL and 592-2972 K/µL, respectively) (Figure 4C, D). Mice treated with vehicle or sorafenib succumbed to disease at 21 days post-transplant with splenomegaly and elevated CD135⁺ (FLT3) leukemic cells in the BM (Fig. 4E, F). In contrast, spleen weights and the number of leukemic cells (measured by their expression of CD135) in the BM of TTT-3002 treated mice were significantly reduced ($P < 0.01$) and these mice appeared healthy at the time of sacrifice (Fig. 4E, F). By comparison, both TTT-3002 (24) and sorafenib are effective against Ba/F3-ITD Luc⁺ cells in vivo under the same dosing schedule, indicating that the presence of the F691L point mutation confers resistance to sorafenib, but not TTT-3002.

In order to further provide proof-of-principle that TTT-3002 is active against sorafenib-resistant cells in vivo, we utilized the Ba/F3-F691L/ITD transplant model to simulate a clinical setting in which a patient relapses while undergoing therapy with sorafenib with selection for a FLT3-F691L/ITD mutation and is treated with TTT-3002 instead. Leukemic mice that received sorafenib (10 mg/kg q.d.) for 2 weeks were administered a single dose of sorafenib or TTT-3002 (6 mg/kg). Leukemic Ba/F3-F691L/ITD cells from the enlarged spleens were harvested 2 hours later, and inhibition of pFLT3 was observed in vivo by TTT-3002, but not sorafenib (Fig. 4G).

**TTT-3002 activity against TKI-resistant relapsed AML patient samples**

Primary leukemic BM samples were obtained from FLT3/ITD⁺ AML patients who had initially responded to sorafenib or AC220 on clinical trials but then had developed
resistance. They had relapsed with a dual D835/ITD mutation or D835 point mutation alone while on a FLT3 TKI (Relapse AML 1-3, supplemental Table 2). Leukemic blasts from these patients were evaluated for their in vitro sensitivity to TTT-3002, sorafenib and AC220, along with a BM sample from a newly diagnosed FLT3/ITD AML patient sample (AML 1) for comparison. Significant effects on proliferation, induction of apoptosis, and cell signaling were observed when each of these samples was treated with TTT-3002 (Fig. 5A-C, supplemental Table 2). The signaling changes were especially prominent in pFLT3 (85-99% inhibition) and pSTAT5 (71-99% inhibition), with variable effects against pAKT (80-86% inhibition in 2/4 samples) and pMAPK (66-73% inhibition in 2/4 samples), dependent on their level and alternative sources of activation. The proliferation IC\textsubscript{50} for TTT-3002 was 3-8nM for relapsed AML samples, and the diagnostic sample (AML1) had an IC\textsubscript{50} of 19nM. The IC\textsubscript{50} for AC220 against relapsed AML samples, however, ranged from 19nM to greater than 50nM, compared to its low nanomolar IC\textsubscript{50} against blasts from the newly diagnosed FLT3/ITD patient (AML1). AC220 was moderately active against blasts from AML 1 and one relapsed patient sample with a D835/ITD mutation (Relapse AML 1) with regard to apoptosis, and was also able to inhibit FLT3 phosphorylation in AML 1 and Relapse AML 3. Sorafenib was active against only AML 1 cells and none of the three relapse samples, with proliferation IC\textsubscript{50} values greater than 50nM, the highest concentration tested. Therefore, TTT-3002 maintains activity against human AML patient samples that have been selected for resistance to the TKIs sorafenib and AC220 in clinical trials.

Plasma protein binding properties of TTT-3002
Only free, non-protein bound levels of TKI are available to bind to target and inhibit its kinase activity. In order to predict the impact of human plasma protein binding on TTT-3002 efficacy in patients, we utilized the PIA assay, which we developed previously to determine the extent of FLT3 inhibition being achieved in clinical trials of multiple FLT3 TKIs (7). The PIA assay is a valuable tool because human plasma contains the entire array of proteins capable of binding to and thus interfering with a TKI’s activity. Utilizing Ba/F3-ITD cells, we compared the IC\textsubscript{50} of TTT-3002 with regard to inhibiting FLT3 phosphorylation (1 h treatment) in media supplemented with 10% FBS (standard culture conditions) to that achieved in 100% mouse or 100% human plasma from healthy donors. We found a 4- and 14-fold shift in IC\textsubscript{50} values, respectively, in mouse and human plasma (Fig. 6A, B and supplemental Table 3). This shift corresponds to approximately 75 and 93% protein binding, which is significantly lower than the binding observed for many other TKIs (7, 39). For example, while the CEP-701 IC\textsubscript{50} for FLT3 inhibition only shifts 6-fold from RPMI with 10% FBS to 100% mouse plasma, the IC\textsubscript{50} shifts greater than 100-fold in 100% human plasma (from 2-3nM to an IC\textsubscript{50} of 700nM), which indicates plasma protein binding of >99% (7). This was the major reason for the failure of CEP-701 to show improved CR and survival rates in a Phase 3 clinical trial (5).

To explore the disparate plasma protein binding of TTT-3002 and CEP-701, the impact of the two major human plasma proteins known to bind many TKIs, AGP and HSA, was evaluated. AGP is an acute phase plasma protein that is often elevated as much as 4-5 fold in leukemia patients (5). To ascertain whether TTT-3002 is significantly bound by this protein, we treated Ba/F3-ITD cells with TTT-3002 or CEP-701 at IC\textsubscript{95}
concentrations ascertained under typical culture conditions (5 and 20nM, respectively) in media supplemented with 0-2 mg/mL AGP and measured the percentage of phospho-FLT3 inhibition by Western blotting. While CEP-701 almost completely loses TKI activity with the addition of just 0.1 mg/mL AGP, the lowest concentration tested, TTT-3002 was still strongly active at physiological AGP concentrations, achieving greater than 60% FLT3 inhibition at 2 mg/mL AGP (Fig. 6C). The other major plasma protein capable of binding many drugs is human serum albumin (HSA). TTT-3002 and CEP-701 activities were not as greatly affected by physiological levels of HSA, the most abundant plasma protein (supplemental Fig. 2A) (40). Thus, TTT-3002 should require lower doses than CEP-701 to achieve sufficient concentrations of free drug in plasma due to lower protein binding to AGP.

**TTT-3002 activity in human leukemia patient plasma**

To further assess the likely activity of TTT-3002 in a clinical setting, human plasma samples were obtained from a panel of adult and pediatric AML patients at the time of diagnosis, when AGP levels are known to often be elevated. Ba/F3-ITD cells were then cultured in these plasma samples with the addition of 0-10nM TTT-3002 for 1 h (Fig. 6D). TTT-3002 potently inhibits phosphorylation of FLT3/ITD in the human AML plasma samples, with an average IC$_{50}$ of 6.4 ± 2.6nM (n=5). There was no significant difference between phospho-FLT3 inhibition achieved in AML patient plasma samples relative to that achieved in normal adult plasma as determined in Fig. 6A, B (IC$_{50}$ = 7.0 ± 0.5nM, n=3). Ba/F3-ITD cells cultured in AML plasma samples supplemented with a fixed concentration of TTT-3002 (20nM) or CEP-701 (100nM) showed that TTT-3002
achieved 75-85% inhibition of FLT3 phosphorylation whereas CEP-701 was inactive under these conditions (Fig. 6E, F). The CEP-701 result in plasma is in stark contrast to what was observed at the same concentrations in cell culture media with 10% FBS and remains the most likely explanation for its failure in clinical trials. We found that TTT-3002 was highly active across the AGP and HSA concentration ranges measured in the plasma samples (0.5-2 mg/mL AGP, 2.5-4.0 g/dL HSA) (supplemental Fig. 2B, C).

**Discussion**

TTT-3002 has been identified as a novel, potent small molecule inhibitor of mutant FLT3 phosphorylation (24). There are a number of mechanisms by which patients can develop resistance to FLT3 inhibition by current TKIs. One such clinical observation is the emergence of resistance mutations in FLT3/ITD expressing cells, which render the cells insensitive to TKI treatment. Other studies indicate that activating point mutations in FLT3, which are found in 7-10% of adult AML cases, provide a survival and proliferative advantage to cells, and respond to many FLT3 TKIs differently than do FLT3/ITD mutants. In the present study, the potent *in vitro* activity of TTT-3002 against a broad spectrum of FLT3/PM activating mutations, as well as a variety of TKI resistance mutations in the FLT3/ITD sequence was demonstrated. TTT-3002 reduced cell viability and inhibited FLT3 autophosphorylation in a dose-dependent manner at low nanomolar to picomolar concentrations. Although only the D835Y variant in the FLT3/ITD allele was tested, inhibition of FLT3/D835F, D835V, D835H and other activating FLT3 point mutations was also demonstrated. This implies that TTT-3002 would also likely target these D835 TKI resistant variants in a FLT3/ITD allele.
Another major factor that limits the efficacy of FLT3 TKIs in clinical trials, aside from lack of activity against FLT3/PMs and selection for TKI resistance mutations in FLT3/ITD, is the extensive protein binding for many TKIs that occurs in human plasma. In the case of CEP-701, the compound is >99.9% protein bound in plasma. Similar binding properties have also been reported for PKC412 (>99%), sorafenib (99.7%) and AC220 (99%) (7, 39, 41). This large amount of protein binding limits the amount of free drug available to inhibit target, reducing the efficacy of some of these TKIs in clinical trials. TTT-3002 shows more moderate protein binding in human plasma (93%). This predicts that the shift in the dose-response curve for TTT-3002 going from cell culture conditions with 10%FBS to human patients should not be as extreme as it is for some other TKIs. Thus, achieving a total level of ≥30nM should achieve >90% FLT3 inhibition, given the average IC$_{90}$ of 2nM against FLT3/ITD phosphorylation by Western blotting. These are the approximate levels that one would aim to achieve at the trough level of the drug and thus would help to determine dose and frequency of administration in a future clinical trial.

The extensive preclinical studies highlighted both here and in a previous manuscript (24) support the advancement of TTT-3002 toward human clinical trials. Further studies will be required to assess the safety and toxicity in nonrodent animal models before moving this compound into human clinical trials, where assessment of absorption, bioavailability, pharmacokinetics and pharmacodynamics can be determined. Drug dosing schedule and tolerance in humans will also need to be determined in Phase 1 trials before moving to trials in relapsed/refractory/resistant FLT3 mutant AML patients.
Acknowledgements

We thank Ting Martin Ma and members of the D.S., P.B. and M.L. laboratories for help, critical comments, technical support and scientific discussions.

References


Association with FAB subtypes and identification of subgroups with poor prognosis.
Blood 2002;99:4326-35.


Table 1. Proliferation IC<sub>50</sub> for FLT3 TKI treatment of FLT3 mutants

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>TTT-3002 (nM)</th>
<th>CEP701 (nM)</th>
<th>Sorafenib (nM)</th>
<th>AC220 (nM)</th>
<th>PKC412 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ba/F3-ITD</td>
<td>0.6</td>
<td>10</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>5</td>
</tr>
<tr>
<td>Ba/F3-F691L/ITD</td>
<td>1</td>
<td>12</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>7</td>
</tr>
<tr>
<td>Ba/F3-D835Y/ITD</td>
<td>0.3</td>
<td>9</td>
<td>&gt;100</td>
<td>47</td>
<td>22</td>
</tr>
<tr>
<td>Ba/F3-N676K/ITD</td>
<td>1</td>
<td>6</td>
<td>36</td>
<td>8</td>
<td>44</td>
</tr>
<tr>
<td>Ba/F3-N676D/ITD</td>
<td>1</td>
<td>6</td>
<td>48</td>
<td>4</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Ba/F3-Y842C/ITD</td>
<td>1.7</td>
<td>17</td>
<td>&gt;100</td>
<td>45</td>
<td>16</td>
</tr>
<tr>
<td>Ba/F3-G697R/ITD</td>
<td>11</td>
<td>55</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Ba/F3 parental</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
</tbody>
</table>
Figure Legends

**Figure 1.** TTT-3002 is active against FLT3 activating point mutations. A, Ba/F3 cells stably transfected with the indicated FLT3 activating point mutations were treated for 48 h, and cell proliferation was measured by MTT assay. Error bars indicate average ± SD, data are representative of three independent experiments. B, Annexin V binding at 48 h following treatment with TTT-3002 or AC220, with error bars indicating average ± SD. The half maximal effective concentration (EC$_{50}$) is indicated on the graph. C, Inhibition of pFLT3 in Ba/F3-FLT3/ITD and FLT3/PM cells. Fraction of pFLT3/FLT3 relative to DMSO treatment is indicated below each blot. D, Quantitation of (C), represented by fraction of pFLT3/FLT3 relative to DMSO control, at 0.5nM and 10nM TTT-3002. Data represent average of three independent experiments ± SD. The half maximal inhibitory concentration (IC$_{50}$) is indicated on the graph.

**Figure 2.** TTT-3002 is active against cells lines containing FLT3 TKI resistance mutations. A, Proliferation of Ba/F3-ITD and Ba/F3-F691L/ITD cells measured by MTT assay at 48 h following treatment with TTT-3002, CEP-701, sorafenib, AC220 or PKC412 (0-50nM). Error bars indicate average ± SD; data representative of three independent experiments. B, Ba/F3 cells transfected with TKI resistance mutations identified in patients (F691L/ITD, D835Y/ITD and N676K/ITD) were treated with TTT-
3002, and inhibition of pFLT3 was assessed by Western blotting of cell extracts. C, Inhibition of pFLT3 with TKI resistance mutations by TTT-3002, CEP-701, sorafenib, AC220 or PKC412, each at 20nM. D, Quantitation of (C), represented by %pFLT3/FLT3 relative to DMSO control. Data represent average of three independent experiments ± SD. E, Inhibition of phospho-STAT5 (pSTAT5), phospho-AKT (pAKT) and phospho-MAPK (pMAPK) in Ba/F3-F691L/ITD and Ba/F3-N676K/ITD cells by TTT-3002, CEP-701, sorafenib, AC220 or PKC412, each at 20nM. Fraction of phospho-protein/total protein, relative to DMSO, is indicated below each blot.

**Figure 3.** Molecular modeling of the FLT3-TKI binding interaction. Orthogonal views of the FLT3 kinase domain (yellow) are shown with the positions of staurosporine (blue, representing theoretical binding of TTT-3002, CEP-701 and PKC412) and sorafenib (green, representing binding of sorafenib and AC220). The side chains of Asn 676, Phe 691, and Gly 697 of FLT3 have been substituted with the side chains of Lys, Leu, and Arg, respectively, to mark the position and nature of common resistance variants and are shown in red.

**Figure 4.** TTT-3002 is active against FLT3-F691L/ITD in vivo. A, Proliferation of Ba/F3-F691L/ITD Luc+ cells at 48 h by MTT assay (0-50nM TTT-3002 or sorafenib). Error bars indicate average ± SD. B, Schematic of, mouse xenograft study. Mice were treated with TTT-3002 (6 mg/kg b.i.d., n=4), sorafenib (10 mg/kg q.d., n=4) or vehicle control (1mM HCl, n=4) for 14 days. C, Hemoglobin (g/dL), D, platelet counts (K/µl), and E, spleen weights of TTT-3002, sorafenib and vehicle treated mice at Day 21 (*, P < 0.05; **, P <
CD135 expressing cells are decreased in TTT-3002 treated mouse BM at Day 21 (**, P < 0.01). G, TTT-3002 is active against sorafenib-resistant FLT3-F691L/ITD phosphorylation in vivo. Mice from the sorafenib cohort (n=2) following treatment with sorafenib for 2 weeks, received a single dose of sorafenib (10 mg/kg) or TTT-3002 (6 mg/kg). Spleens were harvested 2 hours later, and phosphorylation of FLT3 was assessed by Western blotting.

**Figure 5.** TTT-3002 is active against TKI-resistant patient samples with D835 mutations at relapse. A, Inhibition of pFLT3, pSTAT5, pAKT and pMAPK in FLT3/ITD+ (AML1) and relapsed AML patient samples with TKI resistance mutations at residue D835 (Relapsed AML1-3) by TTT-3002, sorafenib or AC220, each at 20nM. Fraction of phospho-protein/total protein, relative to DMSO treated samples, is indicated below each blot. B, Proliferation of AML patient blasts measured by MTT assay at 48 h following treatment with TTT-3002, sorafenib or AC220 (0-50nM). Error bars indicate average ± SD. C, Annexin V binding at 48 h following treatment with TTT-3002, sorafenib or AC220, with error bars indicating average of triplicate samples ± SD. Data represented as percentage Annexin V positive cells relative to DMSO control.

**Figure 6.** TTT-3002 is active in AML patient plasma and has lower affinity for human plasma proteins compared to CEP-701. A, Inhibition of phospho-FLT3 (pFLT3) by TTT-3002 or CEP-701 in Ba/F3-ITD cells cultured in RPMI-1640 with 10% FBS, 100% human plasma, or 100% BALB/C mouse plasma. B, Quantitation of (A), results of three independent experiments represented as %pFLT3/FLT3 relative to DMSO control ± SD.
C, Inhibition of pFLT3 in Ba/F3-ITD cells cultured in RPMI-1640 supplemented with 10% FBS and AGP (0-2 mg/mL) by TTT-3002 (5nM, upper panel) or CEP-701 (20nM, lower panel). Fraction of pFLT3/FLT3 relative to DMSO control is indicated below each blot. Results representative of three independent experiments. D, Inhibition of pFLT3 in Ba/F3-ITD cells cultured in 100% plasma from pediatric (n=2) and adult (n=3) AML patients by TTT-3002 (0-10nM). Data represented as fraction of pFLT3/FLT3 relative to DMSO control. E, Ba/F3-ITD cells cultured in 100% plasma from 3 adults with AML and 3 healthy adults by TTT-3002 (20nM) or CEP-701 (100nM) for 1 h, and analyzed as in (D). Data represented as fraction of pFLT3/FLT3 relative to DMSO control. Error bars indicate average ± SD (n=6; ***, P < 0.0001; **, P = 0.01). F, Representative examples of adult AML plasma (n=3) from (E). Fraction of pFLT3/FLT3 relative to DMSO control is indicated below each blot.
Figure 1

A

%OD vs. DMSO control

D835Y

TTT-3002

AC220

D835V

V579A

Drug Conc. (nM)

B

Annexin V positive cells (%)

EC50

TTT-3002

AC220

Drug Conc. (nM)

C

Ba/F3-ITD

D835Y

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

D

pFLT3/FLT3 vs. DMSO control

IC50

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220

TTT-3002

AC220
Figure 2

A. Ba/F3-ITD

B. Ba/F3-F691L/ITD

C. Ba/F3-ITD

D. Ba/F3-F691L/ITD

E. Ba/F3-D835Y/ITD

Ba/F3-N676K/ITD

Ba/F3-N676D/ITD

Ba/F3-Y842C/ITD

Ba/F3-G697R/ITD

Ba/F3-D835Y/ITD

Ba/F3-N676K/ITD

Ba/F3-ITD

*Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.*
Figure 3
Figure 4

A. \( \text{Ba/F3-F691L/ITD Luc}^+ \)

\[
\text{% OD vs. DMSO control} \quad \text{Drug Conc. (nM)}
\]

- TTT-3002
- Sorafenib

B. Splenomegaly, CD135 expression, histology, sorafenib resistance

Day 0: 2\( \times \)10\(^6\) Ba/F3-F691L/ITD Luc\(^+\) cells (n=12)

Day 7-21: TTT-3002, sorafenib, vehicle

Day 21

C. Hemoglobin (g/dL)

- Normal range: 11.0-15.1

D. Platelets (K/\( \mu \)L)

- Normal range: 592-2972

E. Spleen weight (g)

- Vehicle
- Sorafenib
- TTT-3002

F. CD135\(^+\) cells (%)

- Vehicle
- Sorafenib
- TTT-3002

G. pFLT3, FLT3
Figure 5

A

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>TTT-3002</td>
<td>Sorafenib</td>
<td>AC220</td>
<td>TTT-3002</td>
</tr>
<tr>
<td></td>
<td>DMSO</td>
<td>TTT-3002</td>
<td>Sorafenib</td>
<td>Sorafenib</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>0.07</td>
<td>0.01</td>
<td>0.15</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>0.17</td>
<td>0.98</td>
<td>0.86</td>
<td>0.96</td>
</tr>
<tr>
<td></td>
<td>0.12</td>
<td>0.56</td>
<td>0.81</td>
<td>0.95</td>
</tr>
<tr>
<td></td>
<td>0.05</td>
<td>0.88</td>
<td>0.11</td>
<td>1</td>
</tr>
</tbody>
</table>

B

AML1

Relapse AML1

Relapse AML2

Relapse AML3

C

% Apoptotic

Drug Conc. (nM)

Drug (50nM)
Figure 6

A

<table>
<thead>
<tr>
<th>RPMI w/ 10% FBS</th>
<th>Human Plasma</th>
<th>Mouse Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTT-3002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEP-701</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

TTT-3002

10% FBS in RPMI
HUMAN PLASMA
MOUSE PLASMA

pFLT3/FLT3 vs. DMSO control

CEP-701

pFLT3/FLT3 vs. DMSO control

C

Alpha-1-acid glycoprotein (AGP)

<table>
<thead>
<tr>
<th>Drug Conc. (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>0.1</td>
</tr>
<tr>
<td>0.2</td>
</tr>
<tr>
<td>0.4</td>
</tr>
<tr>
<td>0.8</td>
</tr>
<tr>
<td>1.0</td>
</tr>
<tr>
<td>2.0</td>
</tr>
</tbody>
</table>

TTT-3002

- + + + + + +(TKI)

CEP-701

pFLT3/FLT3 vs. DMSO control

D

CEP-701

Drug Conc. (nM)

F

Adult AML 1

TTT-3002

1 0.26 1.04

CEP-701

1 0.18 1.13

Adult AML 2

TTT-3002

1 0.23 0.88

CEP-701

1 0.18 1.13

Adult AML 3

TTT-3002

1 0.26 1.04

CEP-701

1 0.18 1.13

pFLT3

FLT3
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia

Hayley S. Ma, Bao Nguyen, Amy S. Duffield, et al.

Cancer Res Published OnlineFirst July 24, 2014.